1. |
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e72-e227.
|
2. |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
|
3. |
Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol, 2020, 76(21): 2492-2516.
|
4. |
Tarantini G, Mojoli M, Windecker S, et al. Prevalence and impact of atrial fibrillation in patients With severe aortic stenosis undergoing transcatheter aortic valve replacement: An analysis from the SOURCE XT prospective multicenter registry. JACC Cardiovasc Interv, 2016, 9(9): 937-946.
|
5. |
Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med, 2012, 366(18): 1686-1695.
|
6. |
Seeger J, Gonska B, Rodewald C, et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv, 2017, 10(1): 66-74.
|
7. |
Stortecky S, Buellesfeld L, Wenaweser P, et al. Atrial fibrillation and aortic stenosis: Impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv, 2013, 6(1): 77-84.
|
8. |
European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010, 31(19): 2369-2429.
|
9. |
Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after transcatheter aortic-valve implantation. N Engl J Med, 2020, 382(18): 1696-1707.
|
10. |
Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2016, 9(16): 1706-1717.
|
11. |
McRae HL, Militello L, Refaai MA. Updates in anticoagulation therapy monitoring. Biomedicines, 2021, 9(3): 262.
|
12. |
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J, 2018, 39(16): 1330-1393.
|
13. |
Tanawuttiwat T, Stebbins A, Marquis-Gravel G, et al. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: Insights from the STS/ACC TVT registry. J Am Heart Assoc, 2022, 11(1): e023561.
|
14. |
Mentias A, Saad M, Girotra S, et al. Impact of pre-existing and new-onset atrial fibrillation on outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2019, 12(21): 2119-2129.
|
15. |
Holmes DR, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: A patient-level meta-analysis. J Am Coll Cardiol, 2015, 65(24): 2614-2623.
|
16. |
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg, 2012, 42(5): S45-S60.
|
17. |
Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
|
18. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
19. |
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med, 2021, 385(23): 2150-2160.
|
20. |
Butt JH, De Backer O, Olesen JB, et al. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother, 2021, 7(1): 11-19.
|
21. |
Kawashima H, Watanabe Y, Hioki H, et al. Direct oral anticoagulants versus vitamin K antagonists in Patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv, 2020, 13(22): 2587-2597.
|
22. |
Mangner N, Crusius L, Haussig S, et al. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol, 2019, 123(7): 1134-1141.
|
23. |
Geis NA, Kiriakou C, Chorianopoulos E, et al. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol, 2018, 107(9): 799-806.
|
24. |
Yan J, Liu M, Zhang Y, et al. Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. Clin Cardiol, 2022, 45(10): 1002-1010.
|
25. |
Memon MM, Siddiqui AA, Amin E, et al. Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. Catheter Cardiovasc Interv, 2022, 99(7): 2101-2110.
|
26. |
Ooi AJQ, Wong C, Tan TWE, et al. A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation. Eur J Clin Pharmacol, 2022, 78(10): 1589-1600.
|
27. |
Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest, 2008, 133(6 Suppl): 160S-198S.
|
28. |
Wang KL, Lip GY, Lin SJ, et al. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: Meta-analysis. Stroke, 2015, 46(9): 2555-2561.
|
29. |
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013, 369(22): 2093-2104.
|
30. |
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365(10): 883-891.
|
31. |
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365(11): 981-992.
|
32. |
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361(12): 1139-1151.
|
33. |
Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use: The FRANCE TAVI registry. J Am Coll Cardiol, 2019, 73(1): 13-21.
|
34. |
Didier R, Lhermusier T, Auffret V, et al. TAVR patients requiring anticoagulation: Direct oral anticoagulant or vitamin K antagonist? JACC Cardiovasc Interv, 2021, 14(15): 1704-1713.
|